Home/ Stocks/ SRPT

Sarepta Therapeutics,, Inc. Common Stock

SRPT XNAS

$21.90 +0.24 (+1.12%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$2.30B

About Sarepta Therapeutics,, Inc. Common Stock

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 835 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$2.20B	$-713,410,000	$-7.13
FY 2025	$2.20B	$-713,410,000	$-7.13
Q3 2025	$399.36M	$-50,568,000	$-0.50
Q2 2025	$611.09M	$196.89M	$2.01

Related Market News

No specific coverage for SRPT yet. Check out our latest market news or earnings calendar.

Get SRPT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Sarepta Therapeutics,, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.